Biagio Ricciuti

Company: Dana-Farber Cancer Institute

Job title: Thoracic Medical Oncologist, Senior Scientist

Seminars:

Addressing Acquired Resistance by Predicting Clinical Trial Outcomes & Improving Patient Response Rates 11:30 am

Acquired resistance to mutant-selective RAS inhibitors, including approved and investigational KRAS G12C inhibitors, presents significant challenge. It is critical that we not only consider the efficacy of direct inhibitor targeting but debate how additional drugging of vertical pathways can be crucial to overcoming feedback mechanisms. As recent advances in the last six months have uncovered…Read more

day: Workshop D